• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Diagnosis

Receiving a diagnosis of ALS/MND is a life-changing moment. This page explains what the diagnostic process typically involves and what people can expect in terms of how the disease progresses. It is intended as a general introduction. A neurologist or specialist will be the most important source of information for any individual situation.


How ALS/MND is diagnosed

There is no single test that confirms ALS/MND. Diagnosis is a process, and it can take time. A neurologist will typically conduct a series of assessments to identify signs of ALS/MND and to rule out other conditions that can cause similar symptoms.

The diagnostic process may include:

  • A detailed neurological examination to assess muscle strength, reflexes, coordination, and speech
  • Electromyography (EMG) and nerve conduction studies, which measure the electrical activity of muscles and nerves
  • MRI scans, to rule out other causes of symptoms such as spinal cord compression or stroke
  • Blood and urine tests, to exclude other conditions
  • In some cases, a muscle or nerve biopsy, or a lumbar puncture

Because ALS/MND shares some features with other neurological conditions, reaching a confirmed diagnosis can require multiple appointments and tests over a period of weeks or months. A second opinion from another specialist is a reasonable step, and many people find it helpful.

Once a diagnosis is confirmed, care is typically transferred to, or coordinated with, a multidisciplinary team. This team may include neurologists, physiotherapists, occupational therapists, speech therapists, respiratory specialists, dietitians, social workers, and others. For more on the care team and what it involves, see the Clinical Care section.


How ALS/MND progresses

ALS/MND affects each person differently. The rate and pattern of progression vary from one individual to the next, depending on factors such as which muscles are affected first, age at diagnosis, and overall health.

In most cases, ALS/MND begins with weakness or changes in one area — such as a hand, foot, or the muscles used for speaking or swallowing — and spreads over time to other parts of the body. The muscles that control breathing are typically affected as the disease progresses.

Cognitive and behavioural changes can also occur in some people living with ALS/MND, including difficulties with memory, language, or behaviour. These changes are more common in people who also have frontotemporal dementia (FTD), which overlaps with ALS/MND in a proportion of cases.

Because progression is variable, it is difficult to make precise predictions for any individual. A specialist or multidisciplinary care team is best placed to discuss what to expect based on a person’s specific situation.


Finding support after diagnosis

A diagnosis of ALS/MND affects not only the person diagnosed, but also family members and caregivers. Finding the right support early can make a significant difference.

The Alliance’s member associations provide support, information, and services to people living with ALS/MND and their families around the world. To find an association in your region, visit the Member Association directory.

Note: This page provides general information only. It is not a substitute for medical advice. Anyone with concerns about their symptoms or diagnosis should speak with a qualified healthcare professional.

Primary Sidebar

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Animesh Kumar, India

    Animesh Kumar, India

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • John Dinon, Australia

    John Dinon, Australia

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Mark Miller, UK

    Mark Miller, UK

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Patrick Shuma, Kenya

    Patrick Shuma, Kenya

  • Chen Yin Xue, Taiwan

    Chen Yin Xue, Taiwan

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Glen Elison, USA

    Glen Elison, USA

  • Denis Blais, Canada

    Denis Blais, Canada

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Graham Johnson, Australia

    Graham Johnson, Australia

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Liam Dwyer, England

    Liam Dwyer, England

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Susan Anderson, USA

    Susan Anderson, USA

  • Greg Heydet, USA

    Greg Heydet, USA

  • Bob Simonds, USA

    Bob Simonds, USA

  • Lee Millard, England

    Lee Millard, England

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Liam Dwyer, England

    Liam Dwyer, England

  • Soledad Rodriguez, Spain

    Soledad Rodriguez, Spain

  • Jason Goodman, USA

    Jason Goodman, USA

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Ann Nicol, USA

    Ann Nicol, USA

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Maria Santos Garcia Tellez, Mexico

    Maria Santos Garcia Tellez, Mexico

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Daniel Hare, USA

    Daniel Hare, USA

  • Sally Pauls, USA

    Sally Pauls, USA

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Mirca Bersani, Italy

    Mirca Bersani, Italy
    MircaBersani

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Paul Launer, USA

    Paul Launer, USA

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login